Table 1.
Participants' characteristics at baseline and study end
| Baseline | Placebo Baseline | Study end | P vs. baseline | ATV Baseline | Study end | P vs. baseline | P placebo vs. ATV at baseline |
|---|---|---|---|---|---|---|---|
| N | 12 | 12 | – | 12 | 12 | – | – |
| Men, n (%) | 6 (50) | 6 (50) | – | 6 (50) | 6 (50) | – | – |
| Age (SD) | 58.3 (5.0) | 58.3 (5.0) | – | 58.9 (7.3) | 58.9 (7.3) | – | 0.821 |
| Body mass index, kg m−2 (SD) | 25.3 (1.8) | 25.3 (1.8) | – | 24.2 (4.1) | 24.2 (4.1) | – | 0.405 |
| Total cholesterol, mg dl−1 (SD) | 284 (30) | 289 (35) | 0.844 | 320 (61) | 182 (32) | < 0.001 | 0.078 |
| Low-density lipoprotein, mg dl−1 (SD) | 202 (21) | 206 (34) | 0.469 | 231 (54) | 103 (31) | < 0.001 | 0.102 |
| High-density lipoprotein, mg dl−1 (SD) | 50.6 (13.1) | 51.4 (11.5) | 0.625 | 59.1 (11.6) | 62.3 (11.8) | 0.101 | 0.103 |
| 15-F2t-isoP urinary excretion, ng h−1 (IQR) | 8.0 (6.4–11.1) | 8.9 (7.4–12.3) | 0.721 | 9.8 (6.6–12.5) | 8.4 (6.9–13.3) | 0.875 | 0.763 |
| PLA2s activity, nmol min−1 ml−1 (SD) | 4.35 (0.61) | 5.25 (2.06) | 0.172 | 4.12 (1.14) | 4.45 (0.83) | 0.247 | 0.599 |
| PAF-AH activity, nmol min−1 ml−1 (SD) | 16.7 (2.0) | 17.3 (1.5) | 0.196 | 16.1 (2.8) | 10.9 (2.6) | < 0.001 | 0.552 |
| hsCRP, mg l−1 (IQR) | 1.50 (0.70–2.37) | 1.60 (0.70–2.00) | 0.507 | 1.35 (0.83–1.80) | 0.85 (0.70–2.17) | 0.553 | 0.932 |
PLA2s, Phospholipases A2; PAF-AH, platelet-activating factor acetylhydrolase; hsCRP, ultra-sensitive C-reactive protein.